James Kihara, who serves as Principal Accounting Officer at Acadia Pharmaceuticals, sold 1,030 shares of common stock on April 7, 2026, at prices that ranged from $22.07 to $22.20 per share. The combined proceeds from these multiple transactions amounted to $22,866.
According to the Form 4 filing, the sales were mandatory and executed to satisfy withholding taxes and other tax-related items associated with the vesting of restricted stock units. The filing specifies that the transactions were intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and to be interpreted as meeting the requirements of Rule 10b5-1(c).
These April 7 sales followed a separate action on April 5, when Kihara exercised options on 2,010 shares of common stock. After the April option exercise and the subsequent withholding-related sale, Kihara's direct ownership in Acadia Pharmaceuticals stands at 27,865 shares.
Acadia's stock performance over recent intervals shows mixed movement. Shares have delivered a 51% return over the past year, yet they remain down 17% year-to-date. Market valuation metrics cited in analysis indicate the company trades at a price-to-earnings ratio of 9.54 according to InvestingPro.
Beyond insider activity, Acadia has reported a sequence of corporate and regulatory developments. The European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on Acadia's Marketing Authorization Application for trofinetide, the company's treatment candidate for Rett syndrome. The committee cited concerns about the limited magnitude of the treatment effect and questioned whether the study sufficiently captured all core symptoms of the condition.
Analyst responses to these developments have varied. In one update, BofA Securities lowered its price target on Acadia from $31 to $29 while maintaining a Neutral rating. Separately, another BofA Securities action upgraded Acadia's rating from Neutral to Buy, a move attributed by the firm to a recent share price pullback that it viewed as unrelated to the company's fundamentals.
On the corporate governance front, Acadia announced the appointment of Jonathan M. Poole to its board of directors and to the audit committee. The company noted that Mr. Poole will serve as a Class II director, with his term expiring in 2027.
Taken together, the mandatory insider sale to satisfy tax obligations, the option exercise, regulatory feedback on trofinetide, analyst target and rating adjustments, and the board appointment represent a sequence of administrative, regulatory, and market events unfolding at Acadia Pharmaceuticals.